Substance / Medication

Ozenoxacin

Overview

Active Ingredient
ozenoxacin
RxNorm CUI
1994739

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

4 trials linked to this intervention

4
Total Trials
0
Recruiting
3
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Prevalence of scabies and impetigo worldwide: a systematic review.
Romani Lucia, Steer Andrew C, Whitfeld Margot J et al. · Lancet Infect Dis · 2015
PMID: 26088526Meta-Analysis
The Global Epidemiology of Impetigo: A Systematic Review of the Population Prevalence of Impetigo and Pyoderma.
Bowen Asha C, Mahé Antoine, Hay Roderick J et al. · PLoS One · 2015
PMID: 26317533Meta-AnalysisFull text (PMC)
Interventions for impetigo.
Koning Sander, van der Sande Renske, Verhagen Arianne P et al. · Cochrane Database Syst Rev · 2012
PMID: 22258953Meta-AnalysisFull text (PMC)
Interventions for impetigo.
Koning S, Verhagen A P, van Suijlekom-Smit L W A et al. · Cochrane Database Syst Rev · 2004
PMID: 15106198Meta-Analysis
Ozenoxacin, a New Effective and Safe Topical Treatment for Impetigo in Children and Adolescents.
Torrelo Antonio, Grimalt Ramon, Masramon Xavier et al. · Dermatology · 2020
PMID: 31958794TrialFull text (PMC)
Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial.
Rosen Theodore, Albareda Nuria, Rosenberg Noah et al. · JAMA Dermatol · 2018
PMID: 29898217TrialFull text (PMC)
Systemic bioavailability, safety and tolerability of topical ozenoxacin in healthy adult volunteers.
Gropper Savion, Albareda Nuria, Santos Benjamin et al. · Future Microbiol · 2014
PMID: 25209519Trial
Cumulative irritation, sensitizing potential, phototoxicity and photoallergy of ozenoxacin in healthy adult volunteers.
Gropper Savion, Cepero Ana Luisa, Dosik Jonathan S et al. · Future Microbiol · 2014
PMID: 25209521Trial
Skin tissue exposure of once- versus twice-daily topical ozenoxacin 2% cream: a Phase I study in healthy volunteers.
Gropper Savion, Albareda Nuria, Santos Benjamin et al. · Future Microbiol · 2014
PMID: 25209520Trial
Systemic bioavailability and safety of twice-daily topical ozenoxacin 1% cream in adults and children with impetigo.
Gropper Savion, Cepero Ana Luisa, Santos Benjamin et al. · Future Microbiol · 2014
PMID: 25209523Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Ozenoxacin (substance)
SNOMED CT
763879001
UMLS CUI
C2983945
RxNorm CUI
1994739

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
4
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.